Latest Insider Transactions at Crinetics Pharmaceuticals, Inc. (CRNX)
This section provides a real-time view of insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Crinetics Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Crinetics Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,331
+3.16%
|
$2,331
$1.91 P/Share
|
|
Dec 02
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
10,000
-9.09%
|
$570,000
$57.57 P/Share
|
|
Nov 22
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
501
-0.96%
|
$28,056
$56.52 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-33.52%
|
$776,250
$54.63 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.11%
|
$230,000
$16.89 P/Share
|
|
Sep 26
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
25,000
-18.37%
|
$1,275,000
$51.11 P/Share
|
|
Sep 26
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.52%
|
$375,000
$15.29 P/Share
|
|
Sep 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,035
-1.49%
|
$52,785
$51.5 P/Share
|
|
Aug 26
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-4.13%
|
$159,000
$53.19 P/Share
|
|
Aug 12
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.97%
|
$141,000
$47.68 P/Share
|
|
Jul 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.82%
|
$159,000
$53.43 P/Share
|
|
Jul 25
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
19,056
-14.64%
|
$1,009,968
$53.88 P/Share
|
|
Jul 25
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,056
+12.77%
|
$171,504
$9.28 P/Share
|
|
Jul 15
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,000
-34.33%
|
$1,485,000
$55.0 P/Share
|
|
Jul 15
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,073
+10.18%
|
$547,533
$21.21 P/Share
|
|
Jul 15
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
25,000
-18.37%
|
$1,375,000
$55.0 P/Share
|
|
Jul 15
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.52%
|
$500,000
$20.02 P/Share
|
|
Jul 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.68%
|
$144,000
$48.55 P/Share
|
|
Jul 05
2024
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.89%
|
$660,000
$44.08 P/Share
|
|
Jul 05
2024
|
James Hassard Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.31%
|
$285,000
$19.73 P/Share
|
|
Jul 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-33.52%
|
$632,500
$44.87 P/Share
|
|
Jul 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.11%
|
$230,000
$16.89 P/Share
|
|
Jun 28
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
32,129
-22.43%
|
$1,381,547
$43.61 P/Share
|
|
Jun 28
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,129
+18.32%
|
$289,161
$9.28 P/Share
|
|
Jun 26
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
956
-1.79%
|
$42,064
$44.38 P/Share
|
|
Jun 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.59%
|
$135,000
$45.37 P/Share
|
|
Jun 24
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
9,500
-25.48%
|
$427,500
$45.73 P/Share
|
|
Jun 24
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+20.31%
|
$152,000
$16.89 P/Share
|
|
Jun 21
2024
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.89%
|
$660,000
$44.66 P/Share
|
|
Jun 21
2024
|
James Hassard Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.31%
|
$285,000
$19.73 P/Share
|
|
Jun 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.46%
|
$129,000
$43.86 P/Share
|
|
Jun 07
2024
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+13.42%
|
-
|
|
Jun 07
2024
|
Weston Nichols |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+19.1%
|
-
|
|
Jun 07
2024
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+3.02%
|
-
|
|
Jun 07
2024
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
May 28
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.35%
|
$141,000
$47.49 P/Share
|
|
May 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.24%
|
$147,000
$49.43 P/Share
|
|
May 08
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
107,448
-29.44%
|
$5,264,952
$49.4 P/Share
|
|
May 08
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
107,448
+22.75%
|
$967,032
$9.28 P/Share
|
|
Apr 18
2024
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Direct |
350
-0.14%
|
-
|
|
Apr 15
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-34.1%
|
$632,500
$44.47 P/Share
|
|
Apr 15
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.43%
|
$230,000
$16.89 P/Share
|
|
Apr 15
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+7.2%
|
$20,000
$1.91 P/Share
|
|
Apr 04
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
40,951
-14.69%
|
$2,006,599
$49.17 P/Share
|
|
Apr 04
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,951
+12.81%
|
$368,559
$9.28 P/Share
|
|
Mar 28
2024
|
Stephanie Okey |
SELL
Open market or private sale
|
Direct |
17,500
-74.47%
|
$805,000
$46.38 P/Share
|
|
Mar 28
2024
|
Stephanie Okey |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+42.68%
|
$315,000
$18.29 P/Share
|